HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Kako, Y. Articles by Goldberg, I. J. Search for Related Content PubMed PubMed Citation Articles by Kako, Y. Articles by Goldberg, I. J. Social Bookmarking                      What's this?

Journal of Lipid Research, Vol. 40, 2185-2194, December 1999
Copyright © 1999 by Lipid Research, Inc.

Original Article

Streptozotocin-induced diabetes in human apolipoprotein B transgenic mice: effects on lipoproteins and atherosclerosis

Correspondence to: Ira J. Goldberg

The effects of diabetes and lipoprotein lipase (LpL) on plasma lipids were studied in mice expressing human apolipoprotein B (HuBTg). Our overall objective was to produce a diabetic mouse model in which the sole effects of blood glucose elevation on atherosclerosis could be assessed. Mice were made diabetic by intraperitoneal injection of streptozotocin, which led to a 2- to 2.5-fold increase in plasma glucose. Lipids were assessed in mice on chow and on an atherogenic Western type diet (WTD), consisting of 21% (wt/wt) fat and 0.15% (wt/wt) cholesterol. Plasma triglyceride and cholesterol were the same in diabetic and non-diabetic mice on the chow diet. On the WTD, male diabetic HuBTg mice had a >50% increase in plasma cholesterol and more very low density lipoprotein (VLDL) cholesterol and triglyceride as assessed by FPLC analysis. A Triton study showed no increase in triglyceride or apolipoprotein B production, suggesting that the accumulation of VLDL was due to a decrease in lipoprotein clearance. Surprisingly, the VLDL increase in these mice was not due to a decrease in LpL activity in postheparin plasma. To test whether LpL overexpression would alter these diabetes-induced lipoprotein changes, HuBTg mice were crossed with mice expressing human LpL in muscle. LpL overexpression reduced plasma triglyceride, but not cholesterol, in male mice on WTD. Aortic root atherosclerosis assessed in 32-week-old mice on the WTD was not greater in diabetic mice.

In summary, diabetes primarily increased plasma VLDL in HuBTg mice. LpL activity was not decreased in these animals. However, additional LpL expression eliminated the diabetic lipoprotein changes. These mice did not have more atherosclerosis with diabetes.—Kako, Y., L-S. Huang, J. Yang, T. Katopodis, R. Ramakrishnan, and I. J. Goldberg. Streptozotocin-induced diabetes in human apolipoprotein B transgenic mice: effects on lipoproteins and atherosclerosis. J. Lipid Res. 1999. 40: 2185;–2194.

Supplementary key words: triglyceride, cholesterol, apolipoprotein, heart, coronary

CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this?

This article has been cited by other articles:

				I. J. Goldberg, Y. Hu, H.-L. Noh, J. Wei, L. A. Huggins, M. G. Rackmill, H. Hamai, B. N. Reid, W. S. Blaner, and L.-S. Huang Decreased Lipoprotein Clearance Is Responsible for Increased Cholesterol in LDL Receptor Knockout Mice With Streptozotocin-Induced Diabetes Diabetes, June 1, 2008; 57(6): 1674 - 1682. [Abstract] [Full Text] [PDF]

				E. R. Mohler III, L. Sarov-Blat, Y. Shi, D. Hamamdzic, A. Zalewski, C. MacPhee, R. Llano, D. Pelchovitz, S. K. Mainigi, H. Osman, et al. Site-Specific Atherogenic Gene Expression Correlates With Subsequent Variable Lesion Development in Coronary and Peripheral Vasculature Arterioscler. Thromb. Vasc. Biol., May 1, 2008; 28(5): 850 - 855. [Abstract] [Full Text] [PDF]

				W. Hsueh, E. D. Abel, J. L. Breslow, N. Maeda, R. C. Davis, E. A. Fisher, H. Dansky, D. A. McClain, R. McIndoe, M. K. Wassef, et al. Recipes for Creating Animal Models of Diabetic Cardiovascular Disease Circ. Res., May 25, 2007; 100(10): 1415 - 1427. [Abstract] [Full Text] [PDF]

				L. Wu, R. Vikramadithyan, S. Yu, C. Pau, Y. Hu, I. J. Goldberg, and H. M. Dansky Addition of dietary fat to cholesterol in the diets of LDL receptor knockout mice: effects on plasma insulin, lipoproteins, and atherosclerosis J. Lipid Res., October 1, 2006; 47(10): 2215 - 2222. [Abstract] [Full Text] [PDF]

				I. J. Goldberg and H. M. Dansky Diabetic Vascular Disease: An Experimental Objective Arterioscler. Thromb. Vasc. Biol., August 1, 2006; 26(8): 1693 - 1701. [Abstract] [Full Text] [PDF]

				J. Molnar, S. Yu, N. Mzhavia, C. Pau, I. Chereshnev, and H. M. Dansky Diabetes Induces Endothelial Dysfunction but Does Not Increase Neointimal Formation in High-Fat Diet Fed C57BL/6J Mice Circ. Res., June 10, 2005; 96(11): 1178 - 1184. [Abstract] [Full Text] [PDF]

				R. K. Vikramadithyan, Y. Kako, G. Chen, Y. Hu, E. Arikawa-Hirasawa, Y. Yamada, and I. J. Goldberg Atherosclerosis in perlecan heterozygous mice J. Lipid Res., October 1, 2004; 45(10): 1806 - 1812. [Abstract] [Full Text] [PDF]

				E. P. Lutz, Y. Kako, H. Yagyu, J. Heeren, S. Marks, T. Wright, K. Melford, O. Ben-Zeev, H. Radner, M. Merkel, et al. Mice Expressing Only Covalent Dimeric Heparin Binding-deficient Lipoprotein Lipase: MUSCLES INEFFICIENTLY SECRETE DIMERIC ENZYME J. Biol. Chem., January 2, 2004; 279(1): 238 - 244. [Abstract] [Full Text] [PDF]

				R. H. Eckel, W. W. Barouch, and A. G. Ershow Report of the National Heart, Lung, and Blood Institute-National Institute of Diabetes and Digestive and Kidney Diseases Working Group on the Pathophysiology of Obesity-Associated Cardiovascular Disease Circulation, June 18, 2002; 105(24): 2923 - 2928. [Full Text] [PDF]

				Y. Kako, M. Masse, L.-S. Huang, A. R. Tall, and I. J. Goldberg Lipoprotein lipase deficiency and CETP in streptozotocin-treated apoB-expressing mice J. Lipid Res., June 1, 2002; 43(6): 872 - 877. [Abstract] [Full Text] [PDF]

				C. M. Devlin, G. Kuriakose, E. Hirsch, and I. Tabas Genetic alterations of IL-1 receptor antagonist in mice affect plasma cholesterol level and foam cell lesion size PNAS, April 30, 2002; 99(9): 6280 - 6285. [Abstract] [Full Text] [PDF]

				H. Yagyu, E. P. Lutz, Y. Kako, S. Marks, Y. Hu, S. Y. Choi, A. Bensadoun, and I. J. Goldberg Very Low Density Lipoprotein (VLDL) Receptor-deficient Mice Have Reduced Lipoprotein Lipase Activity. POSSIBLE CAUSES OF HYPERTRIGLYCERIDEMIA AND REDUCED BODY MASS WITH VLDL RECEPTOR DEFICIENCY J. Biol. Chem., March 15, 2002; 277(12): 10037 - 10043. [Abstract] [Full Text] [PDF]

				I. J. Goldberg Diabetic Dyslipidemia: Causes and Consequences J. Clin. Endocrinol. Metab., March 1, 2001; 86(3): 965 - 971. [Full Text]

				J. C. Obunike, E. P. Lutz, Z. Li, L. Paka, T. Katopodis, D. K. Strickland, K. F. Kozarsky, S. Pillarisetti, and I. J. Goldberg Transcytosis of Lipoprotein Lipase across Cultured Endothelial Cells Requires Both Heparan Sulfate Proteoglycans and the Very Low Density Lipoprotein Receptor J. Biol. Chem., March 16, 2001; 276(12): 8934 - 8941. [Abstract] [Full Text] [PDF]

				G. Chen, L. Paka, Y. Kako, P. Singhal, W. Duan, and S. Pillarisetti A Protective Role for Kidney Apolipoprotein E. REGULATION OF MESANGIAL CELL PROLIFERATION AND MATRIX EXPANSION J. Biol. Chem., December 21, 2001; 276(52): 49142 - 49147. [Abstract] [Full Text] [PDF]